Partners in Research

partnersThroughout its history, Gladstone has fostered a collaborative approach to research. Working with a variety of academic and research organizations across disciplines and around the world lets our scientists expand their scientific expertise and technological understanding—in addition to sharing their ideas with others in order to advance biomedical discovery.

Among our current research partners are:

  • Institute for Systems Biology (ISB)— Collaborative studies between Gladstone and the ISB are based on shared interests in neurodegenerative disorders and cardiovascular disease. The studies involve the use of stem cell technology, whole genome sequencing and other systems biology approaches to identify: gene products and drug targets for Alzheimer’s disease and Huntington’s disease; and modifier genes for congenital heart disease. Gladstone Investigators leading the studies are Steve Finkbeiner, MD, PhD, Yadong Huang, MD, PhD, Robert Mahley, MD, PhD, Lennart Mucke, MD and Deepak Srivastava, MD.
  • Global Virus Network (GVN)—is comprised of a worldwide network of preeminent medical virologists and serves as a global resource for the identification, investigation and eradication of viral diseases that pose threats to mankind. Warner Greene, MD, PhD—who directs Gladstone’s virology and immunology research—is also a GVN director. The GVN acts as a resource to government and international organizations providing guidance about viral disease threats, prevention or response strategies—and as an advocate for research and training on virus infections and their disease manifestations—disseminating information to authorities and scientific communities throughout the world.
  • National Resource for Network Biology (NRNB)— Alexander Pico, PhD, who leads the systems biology bioinformatics group at Gladstone, also serves as the executive director of the NRNB. NRNB is a center that helps researchers and clinicians analyze the ever-growing wealth of complex biological data by providing access to tools for conducting advanced studies of biological systems and generating sophisticated models of how human systems function or fail—ultimately leading to new and improved treatments and therapies.
  • Ipierian Inc.—For many years, Gladstone has also collaborated with the biopharmaceutical company iPierian Inc.on new applications for induced pluripotent stem cell (iPS cell) technology. iPierian's focus on iPS cell applications complements Gladstone's commitment to basic biomedical research. Deepak Srivastava, MD, who directs cardiovascular and stem cell research at Gladstone, co-chairs iPierian's scientific advisory board, which includes Gladstone Senior Investigators Benoit Bruneau, PhD, Bruce Conklin, MD, Shinya Yamanaka, MD, PhD, and Lennart Mucke, MD—who also directs neurological research at Gladstone.